Clinical trial
Irofulven in Treating Patients With Metastatic Colorectal Cancer
NCT00003441 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003441 |
|---|---|
| Title | Irofulven in Treating Patients With Metastatic Colorectal Cancer |
| Official title | Phase II Study of MGI-114 (NSC# 683863) Administered Intravenously for Five Days Every 28 Days to Patients With Metastatic Colorectal Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Irofulven (MGI-114) |
| Enrollment | 26 |
| Start date | Aug 1, 1998 |
| Primary completion | Nov 8, 2000 |
| Completion | Nov 8, 2000 |
| First posted | Sep 13, 2004 |
| Last update posted | Oct 25, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: